| Excerpt | Reference |
|---|
| "Young patients with STEMI admitted within 12 hours from symptom onset and treated by primary percutaneous coronary intervention (pPCI) were recruited." | ( Aparci, M; Balta, S; Celik, T; Demir, M; Demirkol, S; Iyisoy, A; Kaya, MG; Kilic, S; Ozturk, C; Unlu, M; Yildirim, OA, 2016) |
| "Among subjects with first-time anterior STEMI due to a proximal or mid LAD lesion who undergo successful PCI, administration of MTP-131 was safe and well tolerated." | ( Bode, C; Chakrabarti, AK; Daaboul, Y; Gibson, CM; Giugliano, RP; Godlewski, J; Halaby, R; Jánosi, A; Kloner, RA; Korjian, S; Merkely, B; Neal, BJ; Spielman, K; Tendera, M; Weaver, WD, 2016) |
| "A total of 153 STEMI patients without early reperfusion therapy were randomly distributed into tirofiban group (therapeutic group, n=78) and non-tirofiban group (control group, n=75)." | ( Li, WM; Liu, Y; Ni, ZH; Wang, HS; Wang, LF; Xia, K; Xu, L; Yang, XC; Zhang, DP, 2016) |
| "In anterior STEMI patients undergoing primary angioplasty, the sooner IV metoprolol is administered in the course of infarction, the smaller the infarct and the higher the LVEF." | ( Aguero, J; Cabrera, JA; Fernández-Friera, L; Fernández-Jiménez, R; Fernández-Ortiz, A; Fuster, V; Galán-Arriola, C; García-Alvarez, A; García-Prieto, J; García-Ruiz, JM; Ibáñez, B; López-Martín, GJ; López-Melgar, B; Macías, A; Martínez-Tenorio, P; Mateos, A; Nuno-Ayala, M; Pérez-Asenjo, B; Pizarro, G; Sánchez-González, J, 2016) |
| "Patients presenting with STEMI and undergoing primary percutaneous coronary intervention in the initial experience with BVS were evaluated and compared with patients treated with everolimus-eluting metal stents (EES) by applying propensity matching." | ( Daemen, J; de Jaegere, P; De Paolis, M; Diletti, R; Fam, JM; Felix, C; Karanasos, A; Onuma, Y; Regar, E; Valgimigli, M; van der Sijde, J; van Geuns, RJ; Van Mieghem, NM; Zijlstra, F, 2016) |
| "Ten patients with STEMI were included; they were randomized to 2 groups: EPC transplantation group (control group; n = 5) and Tβ4-pre-treated EPC transplantation group (experimental group; n = 5)." | ( Fu, G; Song, J; Weng, S; Yu, L; Zheng, H; Zhou, B; Zhu, J, 2016) |
| "This study included 2452 patients with STEMI treated with a primary percutaneous coronary intervention." | ( Borklu, EB; Cinier, G; Eren, M; Hayiroglu, MI; Kaya, A; Keskin, M; Tatlisu, MA; Uzman, O, 2016) |
| "Long-term outcomes of patients with STEMI treated with polymer-free sirolimus- and probucol-eluting stents versus durable-polymer zotarolimus-eluting stents were similar." | ( Byrne, RA; Cassese, S; Colleran, R; Giacoppo, D; Harada, Y; Ibrahim, T; Kastrati, A; Kufner, S; Lahmann, A; Laugwitz, KL; Lohaus, R; Repp, J; Schneider, S; Wiebe, J, 2017) |
| "Fifty-five consecutive STEMI patients were treated using PCLeB (Age 66." | ( Akima, T; Ishikawa, S; Kageyama, T; Kanki, H; Koyama, T; Mitamura, H; Moritani, K; Munakata, M; Shibata, M, 2016) |
| "In patients with anterior STEMI treated with primary PCI, the apoptosis marker M30 might be useful for predicting LV remodeling and subsequent LV systolic dysfunction." | ( Gür, M; Koçyiğit, A; Şeker, T; Selek, Ş; Türkoğlu, C, 2016) |
| "In a real world STEMI network, pre-treatment with ticagrelor in spoke hospitals or in ambulance loading at least 1." | ( Bongo, AS; De Martino, L; Lazzero, M; Lupi, A; Porto, I; Rognoni, A; Schaffer, A; Tessitori, M, 2016) |
| "ST-elevation myocardial infarction (STEMI), which constitutes nearly 25-40 % of current acute myocardial infarction (AMI) cases, is a medical emergency that requires prompt recognition and treatment." | ( Flaherty, JD; Gajjar, M; Ricciardi, MJ; Schimmel, DR; Yadlapati, A, 2016) |
| "In patients with STEMI treated by primary PCI, a 180 mg LD of ticagrelor might be more effective in reducing microvascular injury than a 600 mg LD of clopidogrel, as demonstrated by IMR immediately after primary PCI." | ( Baek, YS; Kim, DH; Kwan, J; Kwon, SW; Lee, MJ; Park, KS; Park, SD; Shin, SH; Woo, SI, 2016) |
| "Overall, 140 patients with STEMI were randomly assigned to receive 400 mg of allopurinol or placebo before treating with streptokinase." | ( Babaei, H; Ghaffari, R; Ghaffari, S; Najafi, H; Separham, A; Ziaee, M, 2016) |
| "In patients with STEMI treated with fibrinolytic therapy, platelet inhibition after clopidogrel is suboptimal and can be further increased with more potent agents." | ( Alves, CM; Barbosa, BR; Caixeta, A; Carvalho, AC; de Souza, CF; Falcão, F; Fonseca, FA; Généreux, P; Guimarães, LF; Pesaro, AE; Silveira, D; Stone, GW, 2017) |
| "In patients with STEMI who were being transported for primary percutaneous coronary intervention, treatment with bivalirudin or with heparin with optional use of GPI resulted in similar 1-year mortality." | ( Anthopoulos, P; Ayesta, A; Bernstein, D; Deliargyris, EN; Fabris, E; Hamon, M; Kilic, S; Soulat, L; Steg, PG; Ten Berg, J; Van't Hof, AWJ; Zeymer, U, 2017) |
| "We studied 1,111 patients with STEMI who received reperfusion treatment (1,032 [92." | ( Angulo-Llanos, R; Devesa, C; Diez-Delhoyo, F; Fernández-Avilés, F; Juárez, M; Martínez-Sellés, M; Sousa-Casasnovas, I; Valero-Masa, MJ; Velásquez-Rodríguez, J; Vicent, L, 2017) |
| "optimal medical therapy in STEMI before and after the set-up of a regional STEMI network that prioritizes PPCI." | ( Bruguera, J; Elosua, R; Fernández, A; García-García, C; Martí-Almor, J; Meroño, O; Miranda, F; Pérez, A; Recasens, LL; Ribas, N; Subirana, I; Tizón-Marcos, H, 2017) |
| "The DAPT-STEMI trial aims to assess in STEMI patients treated with second-generation DESs whether discontinuation of DAPT after 6 months of event-free survival is noninferior to routine 12-month DAPT." | ( Buszman, P; Cook, S; Fabris, E; Kedhi, E; Kennedy, MW; van der Ent, M; von Birgelen, C; Wedel, H; Zijlstra, F, 2017) |
| "From 05/2013 until 11/2014, the STEMI-patients in the Bremen STEMI registry were treated with periinterventional bivalirudin; before and after this period the standard anticoagulative treatment was heparin and provisional GPIs." | ( Backhaus, T; Fach, A; Fiehn, E; Garstka, D; Hambrecht, R; Schmucker, J; Stehmeier, J; Wienbergen, H; Zabrocki, R, 2017) |
| "Among STEMI patients treated with primary percutaneous coronary intervention, small, subclinical elevations of serum creatinine, while not fulfilling the consensus criteria for acute kidney injury, may serve as a significant biomarker for adverse outcomes." | ( Gal-Oz, A; Keren, G; Khoury, S; Margolis, G; Shacham, Y, 2018) |
| "Inclusion criteria: RCTs enrolling STEMI patients treated with primary percutaneous coronary intervention (PCI) and comparing drugs targeting mitochondrial function vs." | ( Ahluwalia, A; Asakura, M; Atar, D; Biscaglia, S; Campo, G; Cerisano, G; Dawson, D; Engstrom, T; Ferrari, R; Frenneaux, M; Galvani, M; Gibson, CM; Ibanez, B; Ishii, H; Jones, DA; Kitakaze, M; Lincoff, AM; Lonborg, J; Morciano, G; Neil, BJ; Ottani, F; Ovize, M; Pavasini, R; Pinton, P, 2017) |
| "Between January 2011 and May 2013, 379 STEMI patients without diabetes undergoing primary percutaneous coronary intervention were randomized to a 4-month treatment with metformin (500 mg twice daily) (N = 191) or placebo (N = 188) in the University Medical Center Groningen." | ( Hartman, MHT; Lexis, CPH; Lipsic, E; Prins, JKB; Schurer, RAJ; van der Harst, P; van der Horst, ICC; van der Horst-Schrivers, ANA; van Veldhuisen, DJ, 2017) |
| "Patients who presented with STEMI within 12 h of symptom onset, treated with primary percutaneous coronary intervention, were randomized to the LL-TS group (n = 47) or the control group (with sham stimulation [n = 48])." | ( Huang, B; Jiang, H; Li, X; Meng, G; Po, SS; Tan, T; Wang, M; Wang, S; Wang, Z; Yu, L; Yuan, S; Zhou, L; Zhou, X, 2017) |
| "In the ABSORB STEMI TROFI II trial, 191 patients with ST-segment elevation myocardial infarction were randomly assigned to treatment with BRS (n = 95) or EES (n = 96)." | ( Brugaletta, S; Cequier, A; Christiansen, EH; Hofma, SH; Iñiguez, A; Jensen, LO; Onuma, Y; Räber, L; Sabaté, M; Serruys, PW; Sotomi, Y; Suttorp, M; van Es, GA; Windecker, S; Yamaji, K, 2017) |
| "Fibrinolysis-treated STEMI patients who received clopidogrel and aspirin at the time of fibrinolysis and were undergoing early PCI frequently had PRU >208." | ( Bagai, A; Booker, J; Cantor, WJ; Cheema, AN; Crawford, JJ; Dehghani, P; Goodman, SG; Harenberg, S; Kelly, S; Lavi, S; Lavoie, A; Mehta, SR; Zimmermann, RH, 2017) |
| "In patients with STEMI planned for PPCI and treated with modern antiplatelet therapy, female gender was an independent predictor of short-term mortality." | ( Alfredsson, J; Cequier, A; Chettibi, M; Goodman, SG; Janzon, M; Montalescot, G; Sederholm Lawesson, S; Swahn, E; Van't Hof, AW; Venetsanos, D, 2017) |
| "All patients with STEMI from the metropolitan area of Bremen, Germany are treated at the Bremen Heart Centre and since 2006 documented in the Bremen STEMI-Registry." | ( Ahrens, W; Becker, M; Bünger, S; Fach, A; Fiehn, E; Günther, K; Hambrecht, R; Pohlabeln, H; Schmucker, J; Seide, S; Wienbergen, H; Würmann-Busch, B; Zabrocki, R, 2018) |
| "Fifty patients with STEMI were randomized to either chewing an LD of ticagrelor, 180 mg, or standard oral administration of an equal dose." | ( Abu-Much, A; Asher, E; Barbash, I; Beigel, R; Chernomordik, F; Elian, D; Fefer, P; Guetta, V; Katz, M; Matetzky, S; Mazin, I; Narodistky, M; Regev, E; Sabbag, A; Segev, A; Tal, S, 2017) |
| "In total, 198 STEMI patients with low left ventricular ejection fraction (LVEF <50%) were randomly assigned to receive intravenous administration of EPO (6,000 or 12,000 IU) or placebo within 6 h of successful percutaneous coronary intervention." | ( Aizawa, Y; Araki, R; Fujio, Y; Higo, S; Hikoso, S; Ishida, Y; Kato, K; Komuro, I; Minamino, T; Nakatani, D; Okutsu, M; Ozawa, T; Suzuki, H; Toba, K; Yamada, T; Yamamoto, K, 2018) |
| "Among patients with STEMI in the ATLANTIC study, pre-hospital administration of ticagrelor improved post-PCI ST-segment resolution and 30-day stent thrombosis." | ( Bagai, A; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Diallo, A; El Khoury, J; Goodman, SG; Hamm, CW; Hammett, CJ; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Merkely, B; Montalescot, G; Storey, RF; Ten Berg, JM; Tsatsaris, A; Van't Hof, AW; Vicaut, E; Zeymer, U, 2018) |
| "The outcome of 760 STEMI patients treated by primary PCI receiving clopidogrel, prasugrel, or ticagrelor (n = 269, 327, 164, respectively) was evaluated." | ( Gach, O; Lancellotti, P; Magne, J; Nyssen, A; Oury, C; Pirlet, C, 2018) |
| "From 2012 to 2015, 1,057 consecutive STEMI patients treated with pPCI in an Italian hub-and-spoke network were prospectively included in an observational registry (RENOVAMI, ClinicalTrials." | ( Alexopoulos, D; Bona, RD; Bongo, AS; Capodanno, D; Gaudio, G; Guasti, L; Lupi, A; Meliga, E; Porto, I; Schaffer, A; Valgimigli, M, 2018) |
| "In this prospective registry of STEMI patients treated with pPCI and contemporary antiplatelet therapy, early escalation to a new generation P2Y12 inhibitor appeared safe and did not significantly affect in-hospital bleeding rates." | ( Alexopoulos, D; Bona, RD; Bongo, AS; Capodanno, D; Gaudio, G; Guasti, L; Lupi, A; Meliga, E; Porto, I; Schaffer, A; Valgimigli, M, 2018) |
| "From 2008 to 2014 we identified 23,800 STEMI patients presenting within 12 hours from symptom onset treated with PPCI and UFH ± GPI or bivalirudin±GPI." | ( Alfredsson, J; Erlinge, D; James, S; Koul, S; Lawesson, SS; Swahn, E; Venetsanos, D, 2018) |
| "Our results demonstrate that in STEMI patients treated with fibrinolytic therapy, switching to ticagrelor was associated with similar bleeding and ischemic outcomes compared with clopidogrel continuation." | ( Abdalla, A; Ahmed, S; Bachuwa, G; Barbarawi, M; Bhatt, DL; Hassan, M; Haykal, T; Hicks, M; Kheiri, B; Osman, M; Zayed, Y, 2018) |
| "4,110 patients were treated for STEMI, mean age 62." | ( Aliprandi-Costa, B; Brieger, D; D Souza, M; French, J; Kritharides, L; Morgan, L; Ranasinghe, I; Snell, LC, 2019) |
| "In patients with STEMI who cannot undergo timely primary PCI, pharmacoinvasive treatment is recommended, comprising immediate fibrinolytic therapy with subsequent coronary angiography and rescue PCI if needed." | ( A Sk Abdul Kader, M; Abdelhamid, M; Alexander, T; AlHabib, KF; Alzubaidi, A; Averkov, O; Aylward, P; Berwanger, O; Contreras Zúñiga, E; Halvorsen, S; Iglesias, R; Zubaid, M, 2018) |
| "In patients with anterior STEMI, early administration of intravenous metoprolol before primary PCI was associated with significantly fewer patients with severely depressed LV GCS and GLS, both at 1 week and 6 months." | ( Ajmone Marsan, N; Bax, JJ; Bucciarelli-Ducci, C; Delgado, V; Fernández-Jiménez, R; Fras, Z; Fuster, V; Ibáñez, B; Montero-Cabezas, JM; Pizarro, G; Podlesnikar, T; Sánchez-González, J, 2019) |
| "CONCLUSIONS Patients with ASTEMI who underwent emergency PCI treatment had good clinical outcomes using intracoronary diltiazem at the distal end of the culprit vessel." | ( Jia, X; Qi, X; Zhang, L, 2018) |
| "Patients with STEMI treated with primary percutaneous coronary intervention (PCI) and second generation zotarolimus-eluting stent." | ( Buszman, P; Cook, S; Delewi, R; Eek, CH; Fabris, E; Hoorntje, JCA; Kedhi, E; Meuwissen, M; Roolvink, V; Schotborgh, CE; Togni, M; van der Ent, M; van Royen, N; van Vliet, R; von Birgelen, C; Wedel, H; Zijlstra, F; Zurakowski, A, 2018) |
| "We retrospectively studied 2339 STEMI patients treated with primary PCI." | ( Keren, G; Khoury, S; Margolis, G; Ravid, D; Rozenbaum, Z; Shacham, Y, 2020) |
| "220 patients with first time STEMI successfully treated with PCI (with or without postconditioning) were recruited from the Postconditioning in STEMI study." | ( Andersen, GØ; Bethke, A; Eritsland, J; Hoffmann, P; Kløw, NE; Shanmuganathan, L; Shetelig, C; Swanson, D, 2018) |
| "In a large cohort of STEMI patients, pre-hospital tirofiban administration was independently associate with a lower risk of high NT-proBNP level after primary PCI, supporting the potential benefit of early antithrombotic treatment administration in STEMI patients." | ( Fabris, E; Giannitsis, E; Hamm, C; Hermanides, RS; Koopmans, PC; Ottervanger, JP; Sinagra, G; Ten Berg, JM; van 't Hof, AWJ, 2019) |
| "In this cohort of patients with STEMI treated by primary PCI, plasmatic NGAL and cystatin C did not provide additional value regarding CI-AKI prediction compared with known risk factors such as baseline creatinine." | ( Barthélémy, O; Collet, JP; Hauguel-Moreau, M; Kerneis, M; Montalescot, G; Nguyen, LS; Silvain, J; Spagnoli, V, 2019) |
| "The 419 consecutive patients with STEMI, treated at one medical center, from March 2010 to December 2015 were retrospectively investigated." | ( Gao, J; Li, J; Li, XW; Si, J; Wang, Y; Wu, QQ; Zhang, LM; Zhang, YH; Zuo, XB, 2019) |
| "Pretreatment of STEMI patients with P2Y12 receptor antagonists was not associated with improved clinical outcomes." | ( Albertsson, P; Angerås, O; Dworeck, C; Erlinge, D; Haraldsson, I; Ioanes, D; Koul, S; Odenstedt, J; Omerovic, E; Persson, J; Petursson, P; Råmunddal, T; Redfors, B; Völz, S, 2019) |
| "Of 1272 consecutive patients with STEMI treated with PCI at our hospital (January 1, 2011, to December 31, 2016), the percentage with achievement of zero, 1, 2, or 3 STEMI care metrics was 7." | ( Abdallah, M; Ballout, JA; Brosovich, D; Ellis, SG; Gullett, TC; Hantz, S; Huded, CP; Johnson, M; Kapadia, SR; Khot, UN; Kralovic, DM; Kravitz, K; Kumar, A; Meldon, SW; Menon, V; Podolsky, SR; Smith, E, 2019) |
| "Among patients age <75 years with STEMI, administration of ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of cardiovascular events when compared with clopidogrel." | ( Averkov, O; Berwanger, O; Damiani, LP; de Barros E Silva, PGM; Fonseca, FA; Goodman, SG; Granger, CB; Guimaraes, HP; Jiang, L; Lopes, RD; Malaga, G; Miranda, TA; Moia, DDF; Nicholls, SJ; Nicolau, JC; Paisani, DM; Parkhomenko, A; Piegas, LS; Santos, RHN; Saraiva, JFK; Tajer, C; Valeis, N; White, HD, 2019) |
| "Multivessel STEMI patients undergoing primary percutaneous coronary intervention (PPCI) and scheduled for a staged percutaneous coronary intervention (PCI) before hospital discharge were selected among those allocated to either prolonged bivalirudin or intra-procedural only bivalirudin infusion in the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) Treatment-Duration study." | ( Adamo, M; Andò, G; Boccuzzi, G; Briguori, C; Calabro', P; Contarini, M; Diletti, R; Frigoli, E; Garcia-Garcia, HM; Garducci, S; Karagiannis, A; Kuku, KO; Limbruno, U; Palmieri, C; Picchi, A; Rigattieri, S; Rothenbühler, M; Russo, F; Sardella, G; Valgimigli, M; Varbella, F; Zimarino, M, 2019) |
| "In 87 statin naïve patients with STEMI treated with primary percutaneous intervention, a non-culprit study plaque in a non-infarct related coronary artery was assessed with OCT at baseline and after 12 months." | ( Antonsen, L; Hansen, HS; Hougaard, M; Jensen, LO; Junker, A; Maehara, A; Mintz, GS; Thayssen, P, 2020) |
| "In total, 185 patients diagnosed with STEMI were enrolled and randomised into either the placebo-treated (n = 88) or rhBNP-treated (n = 97) group." | ( Wang, L; Wei, X; Xie, L; Xie, Z, 2019) |
| "Fifty consecutive patients with STEMI, scheduled to undergo primary angioplasty, were randomly assigned, before intervention, to receive an infusion of GSH (2500 mg/25 mL over 10 min), followed by drug administration at the same doses at 24, 48 and 72 hours elapsing time or placebo." | ( Arrivi, A; Barillà, F; Basili, S; Cammisotto, V; Carnevale, R; Dominici, M; Gaudio, C; Granatelli, A; Lucisano, L; Mangieri, E; Mele, R; Nocella, C; Pennacchi, M; Placanica, A; Raparelli, V; Tanzilli, G; Truscelli, G; Viceconte, N, 2019) |
| "Routine GPI administration in STEMI resulted in a reduction in mortality, driven by reductions in recurrent ischemic events-however predominantly in pre-prasugrel/ticagrelor trials." | ( Brockmeyer, M; Dannenberg, L; Heinen, Y; Jung, C; Karathanos, A; Kelm, M; Lin, Y; Parco, C; Perings, S; Polzin, A; Schulze, V; Wolff, G; Zeymer, U, 2019) |
| "Compared to medication therapy, PCI for STEMI delayed beyond 12 h after the onset of symptoms can better reduce mortality and the incidence of MACEs." | ( Ma, YT; Xie, X; Xiu, WJ; Yang, HT; Zheng, YY, 2019) |
| "We review the outcomes of patients with STEMI treated in our centre at a time when the second-generation DES became the standard of care." | ( Alawami, M; Kasargod, C; Ruygrok, P; Sadler, M; Watson, T; Webster, M, 2019) |
| "Multi-vessel STEMI patients undergoing primary PCI and requiring staged intervention were selected among those randomly allocated to two different bivalirudin infusion regimens in the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) Treatment-Duration study." | ( Adamo, M; Andò, G; Boccuzzi, G; Briguori, C; Calabrò, P; Contarini, M; Diletti, R; Frigoli, E; Garcia-Garcia, HM; Garducci, S; Karagiannis, A; Limbruno, U; Palmieri, C; Picchi, A; Rigattieri, S; Russo, F; Sardella, G; Soud, M; Valgimigli, M; Varbella, F; Yacob, O; Zimarino, M, 2020) |
| "Four hundred and twenty-seven STEMI patients treated with primary percutaneous coronary intervention were included." | ( Benesova, K; Dastych, M; Goldbergová Pavkova, M; Helan, M; Helanova, K; Ince, C; Jarkovský, J; Kala, P; Legrand, M; Littnerova, S; Lokaj, P; Mebazaa, A; Parenica, J; Spinar, J; Tesak, M; Tomandl, J; Tomandlova, M, 2020) |
| "We included 1132 of 2694 patients with STEMI recorded between 1 January 2014 and 31 December 2016 who did not undergo acute reperfusion therapy." | ( Dharma, S; Hak, E; Irawati, S; Nguyen, T; Nursyarofah, N; Taxis, K; Wilffert, B, 2020) |
| "We analyzed 720 consecutive STEMI patients receiving eptifibatide bolus only or conventional treatment in an observational case-control study utilizing propensity score matching of clinical and intervention-specific confounders." | ( Buxy, S; Eberli, FR; Fischer, F; Held, U; Kurz, DJ; Meyer, MR; Senn, O; Zbinden, R, 2021) |
| "In a large, contemporary population of STEMI patients from a LMIC, patients treated with a nPPCI reperfusion strategy had comparable short- and intermediate-term outcomes compared to PPCI despite differences in hospital presentation time and coronary stent use." | ( Alahmad, B; Albaghdadi, MS; ElGuindy, A; Janabi, M; Kassab, M; Kennedy, K; Khanbhai, K; Kholte, D; Khraishah, H; Secemsky, E; Siedner, MJ; Young, MN, 2020) |
| "After PCI for STEMI, patients on dabigatran dual therapy had lower risks of bleeding events versus warfarin triple therapy with similar risks of thromboembolic events, supporting dabigatran dual therapy even in patients with high thrombotic risk." | ( Bhatt, DL; Cannon, CP; Gabor Kiss, R; Hohnloser, SH; Leiva, O; Lip, GYH; Miede, C; Navarro Estrada, J; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM; Zeymer, U, 2021) |
| "Early administration of cangrelor in STEMI patients was associated with more effective platelet inhibition during PPCI and significantly dampened the deleterious inflammatory response compared to standard therapy (NCT03043274)." | ( Abdel-Latif, A; Abo-Aly, M; Chelvarajan, L; El-Helw, M; George, B; Shokri, E; Smyth, SS; Ziada, K, 2021) |
| "In patients with STEMI, who were being transported for primary PCI, early IV BB administration did not significantly affect ST-segment deviation after pPCI compared with placebo." | ( Albarran, A; Alfonso, F; Botas, J; Dambrink, JH; de Smet, B; Fabris, E; Fernández-Avilés, F; Fuster, V; García-Lledó, A; Gosselink, M; Hermanides, R; Hernandez-Jaras, V; Ibanez, B; Kedhi, E; Kolkman, E; Lipsic, E; Mateos-Rodriguez, A; Nijveldt, R; Ottervanger, JP; Piek, JJ; Pizarro, G; Postma, S; Rasoul, S; Remkes, W; Roolvink, V; van 't Hof, AW; van Leeuwen, M; van Royen, N; Zamorano, J, 2020) |
| "ST-segment myocardial infarction (STEMI) is a time-sensitive emergency that requires swift and seamless integration of prehospital and emergency department resources in order to achieve early diagnosis and reperfusion therapy." | ( Berry, BP; Frank, M; Sanders, C, 2021) |
| "We performed a post hoc analysis of STEMI patients in the GLOBAL LEADERS trial comparing experimental ticagrelor monotherapy (1062 patients) with standard 12-month DAPT (1030 patients)." | ( Gamal, AS; Gao, C; Hamm, C; Hara, H; Jüni, P; Kawashima, H; Lunardi, M; Ono, M; Onuma, Y; Serruys, PW; Steg, PG; Tomaniak, M; Vranckx, P; Windecker, S, 2021) |
| "Twenty patients with STEMI were randomized to be treated with rosuvastatin 20 mg QD or simvastatin 40 mg combined with ezetimibe 10 mg QD for 30 days." | ( Bastos, RT; Cruz, ECS; Derogis, PBMC; Dos Santos Ferreira, CE; Faccio, AT; Fonseca, FAH; Fontoura, SC; Izar, MC; Klassen, A; Lopes, AS; Neto, AMF; Picossi, CRC; Sussulini, A; Tavares, MFM, 2021) |
| "In patients with LVT following STEMI, contemporary data of triple therapy with rivaroxaban are lacking." | ( Jiang, Z; Li, D; Qu, M; Si, D; Yang, P; Yu, M; Zhang, Q; Zhang, W; Zhang, Z, 2022) |
| "Among patients who developed LVT after STEMI, we observed differences in efficacy between rivaroxaban plus DAPT therapy and VKA plus DAPT." | ( Jiang, Z; Li, D; Qu, M; Si, D; Yang, P; Yu, M; Zhang, Q; Zhang, W; Zhang, Z, 2022) |
| "Among 123 patients with STEMI after PCI treatment, 73 patients had RA (59." | ( Guo, YJ; Liu, WG; Ma, Z; Ning, B; Wu, D, 2021) |
| "Tirofiban was not associated with RB in STEMI patients treated with emergency PCI." | ( Guo, YJ; Liu, WG; Ma, Z; Ning, B; Wu, D, 2021) |
| "A total of 1270 patients with STEMI treated with percutaneous coronary intervention (PCI) were consecutively enrolled in our study." | ( Luo, S; Shen, J; Wang, L; Xiang, J; Xiang, Z; Xue, Y; Zhou, W; Zhu, Y, 2022) |
| "However, antiplatelet therapy in STEMI patients at high risk of thrombotic events is suboptimal." | ( Gao, Y; Kang, S; Li, X; Liu, Y; Liu, Z; Wang, X, 2023) |
| "The results of the PERI-STEMI trial are expected to provide CMR evidence on whether ARNI could benefit patients with STEMI, so as to facilitate the strategy of CMR-based risk stratification and therapy selection for these patients." | ( Chen, Z; Deng, Q; Diao, K; He, S; He, Y; Huang, B; Li, C; Ma, M; Sun, J; Tang, L; Wang, D; Wang, H; Wang, M; Wu, T; Wu, X; Yan, T; Zhang, L; Zhu, Y, 2021) |
| "Eighty patients with STEMI who underwent primary PCI were randomly allocated 1:1 to treatment with BF-BES or O-SES." | ( Ahlehoff, O; Antonsen, L; Christiansen, EH; Ellert, J; Fallesen, CO; Hansen, KN; Jakobsen, L; Jensen, LO; Maehara, A; Maeng, M; Noori, M; Terkelsen, CJ; Thim, T; Veien, KT, 2022) |
| "In selected patients with STEMI and aspirin hypersensitivity, particularly in the suspect of suboptimal enteric absorption of P2Y12 inhibitors, the use of cangrelor until aspirin desensitization is completed can be considered; bridge therapy to desensitization with glycoprotein IIb/IIIa inhibitors can be considered on a case by case basis, despite the scarce supporting evidence - bridge therapy with indobufen is not recommended due to the limited literature data." | ( Bianco, M; Biolè, C; Cerrato, E; Destefanis, P; Luciano, A; Montagna, L; Spirito, A, 2022) |
| "Among 4370 consecutive STEMI patients treated with PPCI at participating centres, 1188 (27." | ( Bendandi, F; Berti, S; Bruno, AG; De Caterina, AR; Donati, F; Galiè, N; Ghetti, G; Marrozzini, C; Massarelli, G; Mazzone, A; Nardi, E; Palmerini, T; Palmieri, C; Paradossi, U; Pizzi, C; Ravani, M; Saia, F; Taddei, A; Taglieri, N; Trianni, G, 2022) |
| "As compared with men, women with STEMI treated with PPCI have higher risk of both all-cause death and cardiac mortality at 30-day and 1-year follow-up." | ( Bendandi, F; Berti, S; Bruno, AG; De Caterina, AR; Donati, F; Galiè, N; Ghetti, G; Marrozzini, C; Massarelli, G; Mazzone, A; Nardi, E; Palmerini, T; Palmieri, C; Paradossi, U; Pizzi, C; Ravani, M; Saia, F; Taddei, A; Taglieri, N; Trianni, G, 2022) |
| "The presence of STEMI, cardiac arrest, cardiopulmonary resuscitation, hypothermia, vasopressor use, elevated lactate levels, or number of vessels treated did not influence the use of IV antiplatelet agents." | ( Basir, MB; Gorgis, S; Gorwara, S; Justice, L; Kaki, A; Kolski, B; Lalonde, T; Lemor, A; Marso, S; Nazir, R; O'Neill, W; Padgett, R; Rahman, A; Senter, S; Srivastava, N; Zuberi, O, 2022) |
| "In patients diagnosed with USAP, STEMI and NSTEMI, treatment compliance rates were 22." | ( Abusoglu, G; Abusoglu, S; Erdem, K; Eryavuz Onmaz, D; Sivrikaya, A; Unlu, A; Yaglioglu, H, 2022) |
| "Among patients with STEMI treated with fibrinolytic therapy, morphine use was associated with a higher risk of early reinfarction and a lower risk of major bleeding but no difference in mortality." | ( Averkov, O; Berwanger, O; Brass, N; Cantor, WJ; Damiani, LP; Dehghani, P; Goodman, SG; Granger, CB; Lavi, S; Lopes, RD; Lutchmedial, S; Malaga, G; Moia, DDF; Nicholls, SJ; Nicolau, JC; Parkhomenko, A; Piegas, LS; Tajer, CD; Tan, M; White, HD, 2022) |
| "We studied 309 patients with acute STEMI treated with primary percutaneous coronary intervention (pPCI) from the prospective MARINA-STEMI cohort study." | ( Bauer, A; Fink, P; Holzknecht, M; Klug, G; Lechner, I; Mayr, A; Metzler, B; Plangger, J; Reindl, M; Reinstadler, SJ; Tiller, C, 2022) |
| "In patients with STEMI treated with pPCI, inflammatory markers (hs-CRP, IL-6 and fibrinogen) are associated with the presence of LV thrombus." | ( Bauer, A; Fink, P; Holzknecht, M; Klug, G; Lechner, I; Mayr, A; Metzler, B; Plangger, J; Reindl, M; Reinstadler, SJ; Tiller, C, 2022) |
| "The administration of tenecteplase in STEMI patients who received a loading dose with ticagrelor resulted in a significant reduction in MACE compared to alteplase." | ( Demir, M; Günlü, S, 2022) |
| "Consecutive STEMI patients fulfilling inclusion/exclusion criteria were treated with RMS following a standardized OCT-based implantation technique including systematic pre- and post-dilatation, and baseline plus final OCT imaging." | ( Bennett, J; de Hemptinne, Q; Demeure, F; Dugauquier, C; Guédès, A; Iglesias, JF; Picard, F; Pilgrim, T; Vandeloo, B; Warne, DW; Xaplanteris, P, 2022) |
| "Patients with STEMI who required analgesia were randomly assigned in a 1:1 ratio to treatment with intravenous fentanyl or morphine after ticagrelor loading dose (LD) administration." | ( Carbone, F; Degrauwe, S; Iglesias, JF; Lauriers, N; Masci, PG; Valgimigli, M, 2022) |
| "In patients with STEMI undergoing primary PCI, fentanyl did not improve platelet inhibition at 2 hours after ticagrelor pre-treatment compared with morphine." | ( Carbone, F; Degrauwe, S; Iglesias, JF; Lauriers, N; Masci, PG; Valgimigli, M, 2022) |
| "Forty-two STEMI patients treated with thrombolysis were randomized to receive clopidogrel (n = 21) or ticagrelor (n = 21), along with aspirin." | ( Anastasiou, I; Hamilos, M; Kochiadakis, G; Lazopoulos, G; Pagonidis, K; Petousis, S; Skalidis, E; Vardas, P; Zacharis, E, 2022) |
| "Enhanced-dose atorvastatin for STEMI patients improved PCI treatment effect, cardiac function, and vagus nerve function and reduced the incidence of adverse cardiac events." | ( Chen, W; Fan, Z; Han, Z; Huang, C; Liu, J, 2022) |
| "In patients with STEMI treated by PPCI, colchicine administered before PPCI was not associated with a significant reduction in the NRP and MACE prevention (trial registration: IRCT20120111008698N23)." | ( Aghakouchakzadeh, M; Alidoosti, M; Etesamifard, N; Gheymati, A; Hosseini, SH; Jalali, A; Jenab, Y; Kakavand, H; Sadeghian, M; Tajdini, M; Talasaz, AH; Van Tassell, BW, 2022) |
| "Nationwide, registry-based study of STEMI patients treated with primary PCI (2011-17) and subsequently with aspirin and a P2Y12 inhibitor." | ( Bhatt, DL; Butt, JH; Christensen, MK; Fosbøl, EL; Gislason, G; Godtfredsen, SJ; Jørgensen, SH; Kragholm, KH; Køber, L; Leutscher, P; Pareek, M; Sessa, M; Torp-Pedersen, C, 2022) |
| "RBCs from patients with STEMI undergoing primary coronary intervention and healthy controls were administered to isolated rat hearts subjected to global ischemia and reperfusion." | ( Böhm, F; Collado, A; Jiao, T; Jurga, J; Mahdi, A; Pernow, J; Saleh, N; Tengbom, J; Verouhis, D; Yang, J; Zhou, Z, 2022) |
| "In patients with acute anterior wall STEMI undergoing emergency PCI, preprocedural initiation of sacubitril/valsartan therapy increased LVEF and lower NT-pro-BNP concentrations compared with valsartan therapy." | ( Chen, W; Dai, C; Lin, G; Wu, M; Xu, K, 2022) |
| "Patients with STEMI undergoing primary PCI with radial artery access within 48 h of symptom onset who had not received previous fibrinolytic therapy, anticoagulants, or glycoprotein IIb/IIIa inhibitors were randomly assigned (1:1) to receive bivalirudin with a post-PCI high-dose infusion for 2-4 h or unfractionated heparin monotherapy." | ( Dong, S; Guo, J; Han, Y; Jia, Z; Li, S; Li, Y; Liang, Z; Liu, L; Liu, Y; Luo, J; Qin, L; Qiu, M; Stone, GW; Wang, M; Wang, X; Wu, Y; Zhang, H; Zheng, H; Zhong, Y; Zhu, H, 2022) |
| "In patients with STEMI undergoing primary PCI predominantly with radial artery access, anticoagulation with bivalirudin plus a post-PCI high-dose infusion for 2-4 h significantly reduced the 30-day composite rate of all-cause mortality or BARC types 3-5 major bleeding compared with heparin monotherapy." | ( Dong, S; Guo, J; Han, Y; Jia, Z; Li, S; Li, Y; Liang, Z; Liu, L; Liu, Y; Luo, J; Qin, L; Qiu, M; Stone, GW; Wang, M; Wang, X; Wu, Y; Zhang, H; Zheng, H; Zhong, Y; Zhu, H, 2022) |
| "Ninety STEMI patients were prospectively included and randomised to receive either ticagrelor or prasugrel maintenance treatment after successful primary percutaneous coronary intervention." | ( Demirkiran, A; El Messaoudi, S; Everaars, H; Hoeven, NWV; Konijnenberg, LSF; Nijveldt, R; Riksen, NP; Rodwell, L; Royen, NV; van Leeuwen, MAH; van Rossum, AC; Zugwitz, D, 2023) |
| "In revascularised STEMI patients, ticagrelor maintenance therapy did not show superiority over prasugrel in preventing early remote myocardial inflammation as assessed by CMR T1 and T2 mapping." | ( Demirkiran, A; El Messaoudi, S; Everaars, H; Hoeven, NWV; Konijnenberg, LSF; Nijveldt, R; Riksen, NP; Rodwell, L; Royen, NV; van Leeuwen, MAH; van Rossum, AC; Zugwitz, D, 2023) |
| "Ninety STEMI patients were prospectively included and randomised to receive either ticagrelor or prasugrel maintenance treatment after successful primary percutaneous coronary intervention." | ( Demirkiran, A; El Messaoudi, S; Everaars, H; Hoeven, NWV; Konijnenberg, LSF; Nijveldt, R; Riksen, NP; Rodwell, L; Royen, NV; van Leeuwen, MAH; van Rossum, AC; Zugwitz, D, 2023) |
| "In revascularised STEMI patients, ticagrelor maintenance therapy did not show superiority over prasugrel in preventing early remote myocardial inflammation as assessed by CMR T1 and T2 mapping." | ( Demirkiran, A; El Messaoudi, S; Everaars, H; Hoeven, NWV; Konijnenberg, LSF; Nijveldt, R; Riksen, NP; Rodwell, L; Royen, NV; van Leeuwen, MAH; van Rossum, AC; Zugwitz, D, 2023) |
| "Patients with STEMI and a high thrombus burden who underwent thrombus aspiration and primary PCI were randomly allocated to pro-UK administration or control groups." | ( Cao, M; Gao, J; Meng, X; Wang, Z; Xu, Z; Yu, S; Zhang, H; Zhu, W, 2022) |
| "Patients with STEMI and a high thrombus burden who underwent thrombus aspiration and primary PCI were randomly allocated to pro-UK administration or control groups." | ( Cao, M; Gao, J; Meng, X; Wang, Z; Xu, Z; Yu, S; Zhang, H; Zhu, W, 2022) |
| "Patients with STEMI treated using PCLeB have reported positive outcomes." | ( Koyama, T, 2023) |
| "Among 1,139 patients with STEMI due to de novo disease, 452 were treated with DCBs and 687 with DES." | ( Bhalraam, U; Corballis, N; Eccleshall, SC; Gilbert, T; Gunawardena, T; Maart, C; Mamas, MA; Merinopoulos, I; Mohamed, MO; Perperoglou, A; Reinhold, J; Richardson, P; Ryding, A; Sarev, T; Sawh, C; Sulfi, S; Vassiliou, VS; Wickramarachchi, U; Wistow, T, 2023) |
| "A total of 127 patients with STEMI treated by primary PCI were studied." | ( Han, L; Han, S; Hu, C; Lu, Y; Meng, Y; Wang, J; Wu, P; Xu, K; Xu, Y, 2023) |
| "In Patients with STEMI, intracoronary thrombus architecture was significantly altered between patients pre-treated with prasugrel when compared to clopidogrel." | ( Baas, L; Gawaz, MP; Geisler, T; Gekeler, S; Harm, T; Kreisselmeier, KP; Müller, II; Müller, KAL; Prang, C; Rath, D; Schröder, S, 2023) |
| "In a real-word STEMI population the prognosis of patients has improved in the last decades, and this was associated to the use of new antithrombotic treatments and to the implementation of complete revascularization." | ( Boldrin, C; Fabris, E; Gagno, G; Giannini, F; Gregorio, C; Perkan, A; Pezzato, A; Sinagra, G, 2024) |
| "In this study, we selected STEMI patients who underwent PPCI treatment in our hospital from October 2019 to December 2021 were selected as the study subjects, of which 46 received intravenous injections of rhBNP (research group), and 36 STEMI patients underwent PPCI (control group)." | ( Hou, Y; Li, K; Lin, L; Liu, Y; Tang, M; Wang, Q; Wu, J; Xie, C; Yang, P, 2023) |
| "A total of 80 STEMI patients admitted to our hospital from February 2020 to March 2023 were selected and included in the retrospective study, all receiving PCI treatment." | ( Bao, WW; Liu, DL; Liu, XT; Zeng, XM; Zhang, Z, 2023) |